In total, these analyses show that a combination of ER, HER2, and a single proliferation biomarker (i.e., AURKA) is prognostic, but is suboptimal to capture the biological diversity of breast cancers, which has similar implications for the capture of this biological diversity using IHC-based methods. This evidence concerns the gene ESR1 and breast carcinoma.